Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies
Oncology Communications · 29.01.2026 · 1 (1) · 5-7
DOI: 10.62762/oc.2025.306213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Communications, online erschienen am 29.01.2026. Verfasst von Wenmei Jiang und 8 weiteren Autor:innen. Gefördert von: Zhejiang Provincial Medical Health Science and Technology Project, Zhejiang Provincial Cancer Hospital Cultivation Fund.
Abstract (Originalsprache)
The article by Piffkó A et al. elucidates the double-edged sword role of radiotherapy in cancer treatment. Radiotherapy stimulates tumor cells to secrete amphiregulin (AREG), which in turn activates EGFR$^+$ tumor-associated mononuclear phagocytes (MNPs). This activation feeds back into the EGFR signaling pathway, impairing the anti-tumor functions of MNPs. Moreover, AREG upregulates the expression of the immune checkpoint protein CD47 in tumor cells, thereby enabling them to evade immune-mediated phagocytosis. These insights hold important implications for clinical trial design and for optimizing therapeutic strategies.
Förderung
- Zhejiang Provincial Medical Health Science and Technology Project
- Zhejiang Provincial Cancer Hospital Cultivation Fund
Zitieren
APA
Jiang, W., Huang, X., Tian, J., Wu, Y., Zhao, J., Luo, T., Zeng, J., Cai, S., & Wu, L. (2026). Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies. Oncology Communications, 1(1), 5-7. https://doi.org/10.62762/oc.2025.306213
Vancouver
Jiang W, Huang X, Tian J, Wu Y, Zhao J, Luo T, et al. Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies. Oncology Communications. 2026;1(1):5-7. doi:10.62762/oc.2025.306213
BibTeX
@article{Jiang2026,
author = {Jiang, Wenmei and Huang, Xiancong and Tian, Jiayuan and Wu, Yimin and Zhao, Jiazheng and Luo, Taobo and Zeng, Jian and Cai, Shunv and Wu, Leilei},
title = {Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies},
journal = {Oncology Communications},
year = {2026},
volume = {1},
number = {1},
pages = {5--7},
doi = {10.62762/oc.2025.306213}
}
EUVIMED